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ABSTRACT 
 
The role of systemic corticosteroid therapy in Non Arteritic Anterior Ischaemic 
Optic Neuropathy 
 
AIM:To look for improvement in visual acuity,visual fields and rate of resolution 
of optic disc edema in NA-AION after treatment with oral 
corticosteroids.METHOD:40 patients were diagnosed as NA-AION in acute 
phase.20 patients among them were randomly selected for steroid therapy with 
60mg oral prednisolone once daily for 2 weeks,tapered by 5mg every 5 days to 
40mg either till the disc showed no edema or upto a maximum of 2 months and 
then rapidly tapered off.20 other patients were treated with placebo(oral vitamin 
C). Visual acuity and visual fields were assessed during completion of therapy & at 
6 months.RESULTS:At 6 months from onset of NA-AION,visual acuity improved 
in 80% in treated group and 30% in control group. Visual fields improved in 40% 
in treated group and 30% in control group. Optic disc edema resolved earlier in 
70% in treated group and 20% in control group.CONCLUSION:Oral 
corticosteroids in acute phase of NA-AION cause significant improvement in 
visual acuity, visual fields & rate of resolution of optic disc edema.  
Keywords: Non arteritic anterior ischaemic optic neuropathy, corticosteroids, optic 
disc edmema  
PART –I 
INTRODUCTION 
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INTRODUCTION 
 Ischaemic optic neuropathy is an acute vascular optic neuropathy 
presenting with sudden “stroke like” vision loss in elderly patients. When 
the anterior portion of the optic nerve supplied by the posterior ciliary 
artery circulation is involved, it is Anterior Ischaemic Optic Neuropathy 
(AION). Posterior Ischaemic Optic Neuropathy (PION) involves that part 
of the optic nerve which does not receive blood supply from the posterior 
ciliary arteries. Etiologically, Ischaemic optic neuropathy can be 
classified as arteritic and non-arteritic types.  The most common type of 
acute optic neuropathy in elderly people is Non Arteritic Anterior 
Ischaemic Optic Neuropathy (NA-AION) with an annual incidence of 
2.3-10.2 per 100000 population.  
APPLIED ANATOMY 
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APPLIED ANATOMY 
THE OPTIC NERVE- STRUCTURE 
 The axons taking origin from the ganglion cells form the retinal 
nerve fibre layer which continues backward as the optic nerve. 
The length of the optic nerve is 47-50 mm. It is divided into four 
parts:  
Intraocular part measures 1 mm 
Intraorbital part measures 30 mm  
 Intracanalicular part measures 6-9 mm 
 Intracranial part measures 10 mm  
INTRAOCULAR PART 
Its average horizontal diameter is 1.5 mm and vertical diameter is 1.8 
mm. it consists of surface nerve fibre layer, prelaminar portion, lamina 
cribrosa and retrolaminar portion from anterior to posterior.  
Surface nerve fibre layer 
It consists of axons originating from the ganglion cells which 
converge on the optic disc. The optic disc is ensheathed by an internal 
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limiting membrane made of astrocytes. This layer separates it from the 
vitreous and is continuous with the internal limiting membrane of retina. 
Prelaminar region 
It consists of neurons and astroglial tissue. The border tissue of Jcoby 
separates the nerve from the choroid. 
Lamina cribrosa 
It consists of fenestrated sheets of scleral connective tissue lined by 
glial tissue. The optic nerve fibre bundles leave the eye through these 
fenestrations. A rim of collagenous tissue admixed with glial cells 
between the choroid and the sclera and optic nerve fibres is the border 
tissue of Elschnig. 
Retrolaminar region 
In this region astrocytes are reduced and myelin is acquired from 
oligodendrocytes. Hence the optic nerve diameter is nearly doubled to 3.0 
mm.   
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INTRAORBITAL PART 
The part of the optic nerve from behind the eye to the optic foramina 
is the intraorbital part. The ophthalmic artery runs above the optic nerve 
laterally to medially.   
INTRACANALICULAR PART 
The ophthalmic artery crosses optic nerve from medial to lateral side 
inferiorly 
INTRACRANIAL PART 
The cavernous sinus is located below it. This part forms the optic 
chiasma posteriorly after uniting with its counterpart from the 
contralateral side. This part is ensheathed by pia mater, but receives 
arachnoid and dural sheaths at the point of its entry into the optic canal. 
BLOOD SUPPLY OF THE OPTIC NERVE 
The posterior ciliary arteries with a small contribution from central 
retinal arteries supply the optic nerve. The anterior and posterior parts of 
the optic nerve receive blood supply from different sources.  
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Surface nerve fibre layer: 
It is supplied by capillaries derived from the retinal aterioles which 
anastamose with the vessels from the prelaminar region. Occasionally, a 
ciliary derived vessel from the prelaminar region may enlarge to form the 
cilioretinal artery. 
 
Figure 1 – schematic representation of blood supply of optic nerve 
Prelaminar region: 
It is supplied by vessels of ciliary region. These vessels are derived 
from separate branches of short PCAs. 
Lamina cribrosa region: 
It is also supplied by ciliary vessels. They commonly arise from short 
PCAs and the arterial anastamosis of Zinn-Haller. 
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Retrolaminar region: 
It is supplied by recurrent pial vessels of the ciliary circulation and 
centripetal and centrifugal branches of the central retinal artery. 
Hence, the major blood supply to the optic nerve head is by the short 
Posterior Ciliary Arteries and peripapillary choroid. 
 
Figure 2- schematic representation of blood supply of nerve fibre layer, 
prelaminar,laminar and retrolaminar parts of optic nerve 
Blood supply of the posterior portion of the optic nerve: 
Peripheral centripetal vascular system- it is formed by the pial vessels 
which come from collateral arteries arising from the ophthalmic artery. 
Axial centrifugal vascular system- it is formed by branches arising 
from the central retinal artery and is seen in 75% of cases. 
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Posterior ciliary arteries: 
There may be 1-5 PCAs but usually 2 or 3 PCAs are present in one 
eye. 
1.  Long PCAs- usually medial and lateral arteries - supply the medial 
and lateral parts of the peripheral choroids. They do not supply the 
optic nerve head. 
2. Short PCAs (SPCAs)- usually upto 20 in number.   
a)  Paraoptic SPCAs- few SPCAs enter the eyeball closest to the 
optic nerve and form the major supply of the optic nerve head. 
b)  Distal SPCAs-enter the eyeball midway between the paraoptic 
SPCAs and long PCAs and form the major supply of the choroids. 
The number and blood supply of the PCAs vary from one individual 
to the other. The PCAs and their subdivisions are endarteries and hence 
watershed areas are present in the zones of blood supply of the posterior 
ciliary arteries.The importance of these watershed zones is that when the 
perfusion pressure drops in any of the endarteries6, these zones become 
most vulnerable to ischaemia. This plays an important role in ischaemic 
optic neuropathy.  
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The inter- and intra- individual variations in the PCA distribution in 
blood supply results in varying patterns and manifestations of ischaemic 
optic neuropathy.  
 
Figure 3- schematic representation of the various locations of watershed 
zones in optic nerve. 
ETIOLOGY AND 
PATHOGENESIS 
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ETIOLOGY AND PATHOGENESIS 
FACTORS AFFECTING BLOOD FLOW IN THE OPTIC NERVE 
HEAD AND ITS PATHOPHYSIOLOGY: 
Ischaemic optic neuropathy occurs when the blood flow in the optic 
nerve head is impaired. The blood flow in the optic nerve head is 
influenced by  
Arterial blood pressure,  
Intraocular pressure and  
Resistance to blood flow.  
The ONH blood flow is calculated by the following formula:  
Perfusion pressure is the difference between Mean arterial blood 
pressure and venous blood pressure in a vascular bed. Normally the 
intraocular pressure is slightly lower than the central retinal venous 
pressure at the optic disc. Hence, perfusion pressure is the difference 
between Mean arterial blood pressure and the intraocular pressure7. 
Mean BP = Diastolic BP + 1/3 (systolic minus diastolic BP) 
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Autoregulation of blood flow and endothelial derived vasoactive agents 
affect BP and resistance to blood flow.  
AUTOREGULATION OF BLOOD FLOW 
When changes occur in the perfusion pressure, the blood flow to the 
tissues and capillary pressure get altered and it is Autoregulation that 
helps in maintaining a fairly constant blood flow. Autoregulation is 
stimulated by changes in resistance of the blood vessels which occurs due 
to alterations in the vascular tone. Autoregulation occurs only when the 
perfusion pressure is within a particular range. 
 
Figure 4- Autoregulation at different perfusion pressure ranges 
NA-AION can occur due to impaired autoregulation of the ONH 
blood flow caused by systemic hypotension. 
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Autoregulation can be affected by systemic hypertension and 
hypotension, arteriosclerosis,diabetes,atherosclerosis, hyperlipidemia 
and vasculitic disorders11. 
ENDOTHELIAL DERIVED VASOACTIVE AGENTS 
The endothelial vasodilators like nitric oxide and vasoconstrictors 
like endothelin control the vascular tone. The autoregulation of blood 
flow and the vascular tone is also influenced by the endothelial cells8. 
 
Figure 5- balance between vasodilators and vasoconstrictors 
ARTERIAL BLOOD PRESSURE 
Arterial hypertension can interfere with the ONH blood flow by 
causing increased vascular resistance in terminal arterioles or secondary 
changes in ONH blood flow autoregulation due to abnormalities in 
Endothelial Derived Vasoactive Agents 
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INTRAOCULAR PRESSURE 
During sleep, rise in IOP and concurrent  nocturnal arterial 
hypotension causes  marked fall of perfusion pressure in the ONH. This 
is an important hidden risk factor for NA-AION9. 
RESISTANCE TO BLOOD FLOW 
It is influenced by caliber of the vessels feeding the ONH and 
rheological properties of the blood. 
NON ARTERITIC ANTERIOR ISCHAEMIC OPTIC NEUROPATHY 
NA-AION occurs due to vasculopathy involving the para-optic 
branches of short posterior ciliary arteries but the choroidal circulation is 
uninvolved. It may be due to transient absence or reduction in perfusion 
of the vessels or rarely due to embolism of the vessels that supply the 
ONH. The optic nerve head is supplied mainly by the PCA circulation. 
But it is not necessary for complete occlusion of the PCA for NA-AION 
to occur4. When the perfusion pressure is reduced, the vessels in the 
prelaminar portion of the ONH are most susceptible to obliteration 
followed by peripapillary choroid, watershed zone and rest of the 
choroid.  
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RISK FACTORS 
PREDISPOSING FACTORS 
 Arterial hypertension 
 Diabetes mellitus 
 Hyperlipidemia 
 Ischaemic heart diseas 
 Cerebro vascular disease 
 Migraine 
 Prothrombotic conditions – lupus anticoagulant, ACL antibody, 
factor 5, protein C & S deficiency, anti thrombin deficiency 
 Hyper homocysteinemia 
 Drugs – sildenafil, alpha interferon, amiodarone 
PRECIPITATING FACTORS 
 Nocturnal hypotension 
 Sleep apnea 
OCULAR FACTORS 
 Chronic simple glaucoma 
 ONH drusen 
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COMPARTMENT SYNDROME IN NA-AION 
Optic disc in NA-AION is usually of small diameter with a small or 
absent cup. This causes chronic mechanical obstruction to axoplasmic 
flow at the level of cribriform plate with resultant intracellular axonal 
swelling. This axoplasmic stasis causes secondary compression and 
further microvascular compromise. The decreased return of 
neurotrophins causes additional ganglion cell death.5 This compartment 
syndrome if unrelieved leads to cavernous degeneration of the axons. 
CLINICAL FEATURES 
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CLINICAL FEATURES 
SYMPTOMS 
Loss of vision in NA-AION occurs over hours to days and more 
commonly upon awakening. It mostly involves the inferior field of 
vision. The vision loss is either static or progressive until stabilization.  
SIGNS 
Visual acuity in NA-AION is more than 6/60 in 58-60% cases. Colour 
vision loss parallels visual acuity loss.  
Visual field defects of any form can occur but altitudinal field defect 
(usually inferior) is more common and is seen in 55-80% cases.  
Optic disc edema is either diffuse or segmental12, hyperemic or pale. 
Peripapillary retinal hemorrhages are common. Retinal exudates are 
unusual. Optic disc in contralateral eye usually has a small diameter with 
a small or absent cup. This structural crowding of axons is called a “disc 
at risk”10.  
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Fig 6- diffuse hyperaemic disc edema in NA-AION 
 
Figure 7- diffuse pallid disc edema with splinter hemorrhage  
in NA-AION 
 
 
Figure 8- inferior segmental disc edema with  
splinter hemorrhage in NA-AION 
17 
 
 
Figure 9- disc pallor after 8 weeks in NA-AION 
 
Figure 10- disc pallor with cupping in A-AION 
 
Figure 11- disc at risk in NA-AION 
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Figure 12- AP showing inferior altitudinal field defect  
typical of NA-AION 
 
 
 
 
ARTERITIC AND NON 
ARTERITIC AION 
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ARTERITIC & NON ARTERITIC AION 
FEATURES NA-AION AAION 
Age 50 years and above 
usually 
60 years and above 
usually 
Headache, 
claudication, scalp 
tenderness, temporal 
artery induration 
Less common More common 
Transient visual loss Rare Common 
Visual acuity 6/60 or better usually Worse than 6/60 
usually 
Fundus- 
1.  Optic disc edema 
2.  Fellow eye -optic 
disc     
3. After 4-8 weeks  
Hyperemic/ pallid 
Diffuse/ segmental 
“Disc at risk” 
 
Optic atrophy 
Pallid and segmental- 
more common 
Normal Cup disc ratio 
 
Optic atrophy with 
cupping 
FFA Only disc delay Choroidal delay with 
disc delay 
ESR Less than 50 usually More than 70 usually 
Contralateral eye 
involvement 
14% 54-95% 
Visual acuity recovery Stable/ progressive/ 
recovery 
Recovery unusual 
DIFFERENTIAL DIAGNOSIS 
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DIFFERENTIAL DIAGNOSIS 
FEATURES NA-AION OPTIC NEURITIS 
Age usually 50 years and 
above 
Usually young 
Pain with eye 
movement 
Absent present 
Optic disc edema Diffuse / segmental 
Hyperemic/ pallid 
Diffuse and hyperemic 
without hemorrhages 
FFA Disc delay Normal filling of disc 
MRI brain Usually normal Optic nerve swelling/ 
enhancement is 
common 
 
FEATURES NA-AION 
DISC EDEMA DUE 
TO COMPRESSIVE 
LESIONS 
Visual acuity loss Relatively rapid Insiduous onset, 
gradually progressive  
Orbital disease with 
proptosis, lid or EOM 
involvemnt 
Absent Can be present 
After 4-6 weeks Atrophy develops Disc edema persists 
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FEATURES NA-AION 
DIABETIC 
PAPILLOPATHY 
H/O Diabetes mellitus Not always 70%- type 1 DM, 
30% type 2 DM 
Optic disc edema Usually unilateral Bilateral in 40% 
Visual acuity loss 6/60 or better 6/12 or better if not 
a/w maculopathy 
Optic nerve 
dysfunction 
Present Absent 
 
MANAGEMENT 
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MANAGEMENT 
INVESTIGATIONS 
FEATURES INVESTIGATIONS 
Typical presentation of NA-AION 
with no symptoms/signs of GCA 
and normal ESR and CRP 
 Control of DM, HTN, 
Hyperlipidemia 
Atypical course with pain, 
persistent disc edema for more than 
2 months, progressive visual loss 
beyond 2 months, recurrence after 2 
months 
Neuroimaging 
Orbital ischaemia Carotid doppler 
Age less than 50 Serum Homocysteine 
Clinical features of thrombosis/ 
vasculitis 
Work up for pro thrombotic 
conditions and vasculitis 
 
CLINICAL COURSE 
VISUAL ACUITY 
Untreated NA-AION Usually stable 
Untreated NA-AION (progressive 
form) 
Worsens in 1-2 months, with no 
further deterioration 
Untreated NA-AION (spontaneous 
recovery) 
13-42% cases 
Recurrence in affected eye after 2 
months 
3 % cases  
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VISUAL FIELDS 
Improvement in mean sensitivity or retinal 
threshold sensitivity by atleast 2dB 
24% cases 
 
OPTIC NERVE HEAD 
Optic disc edema subsides in 4-6 
weeks 
Diffuse / sectoral atrophy develops 
Persistent disc edema after 6 weeks Alternate diagnosis to be thought of 
 
ROLE OF ORAL CORTICOSTEROIDS IN NON ARTERITIC 
-ANTERIOR ISCHAEMIC OPTIC NEUROPATHY 
The major pathology is stasis of axoplasm due to ischaemia that 
clinically presents as optic disc edema. As a secondary change the axonal 
swelling occuring in a crowded disc causes compression of capillaries 
and fluid leakage. This aggravates the ischaemia forming a vicious cycle1. 
Corticosteroids break this vicious cycle and cause faster optic disc 
edema resolution. They reduce the capillary permeability and cause 
progressive decrease of compression of capillaries in the ONH2. Thus 
they improve the functioning of the surviving but non functioning 
hypoxic axons. Visual acuity and visual fields improve upto 6 months if 
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oral corticosteroid therapy is started within few weeks of onset of 
NA-AION13. 
The following modalities of treatment that were tried for NA-AION 
were found to be ineffective3.  
 Optic nerve sheath decompression  
 Aspirin 
 Levodopa/ carbidopa 
 Brimonidine 
 Hyperbaric oxygen 
PREVENTION 
Though there is no proven prophylactic measure for NA-AION, 
Aspirin is recommended in NA-AION for its role in reducing the risk for 
stroke and myocardial infarction. 
PART II  
AIM AND OBJECTIVES 
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AIM AND OBJECTIVES 
PRIMARY OBJECTIVE: 
   To assess improvement in visual acuity and visual fields following 
treatment with oral corticosteroids in NA-AION during the acute phase  
SECONDARY OBJECTIVE:  
    To assess the rate of resolution of optic disc edema in NA-AION 
following treatment with oral corticosteroids 
MATERIAL AND METHODS 
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MATERIALS AND METHODS 
STUDY CENTRE: Neuro-ophthalmology services, RIOGOH,Chennai 
STUDY DESIGN: Prospective study 
INCLUSION CRITERIA: 
Patients in the age group of 50 years and above of either sex 
presenting with 
 Sudden onset painless defective vision (presenting within 2 weeks of 
onset) 
 Visual acuity worse than 6/12 
 Optic disc edema (suggestive of acute phase of NA-AION) which can 
be hyperaemic/pallid, diffuse/segmental with or without  splinter 
haemorrhages, small or absent cup in either eyes 
 Visual fields showing altitudinal/sectoral/ arcuate defects 
 FFA showing disc delay without choroidal delay 
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EXCLUSION CRITERIA: 
 Transient obscuration of vision/claudication  
 ESR >50mm/hour 
 Scalp tenderness or induration/cordlike firmness/ nodularity of 
temporal artery region 
 Recurrent NA-AION in the same eye 
 Bilateral NA-AION 
 Patients who had a diagnosis of glaucoma & visual field loss 
 Patients who are having DM with RBS >140 mgs/dl or diabetic 
retinopathy other than mild non proliferative diabetic retinopathy  
 Patients with immunocompromised status 
 Peptic ulcer disease 
 Pregnant females 
 Presence of infectious /inflammatory disease that could be 
responsible for optic disc edema 
 Presence of other ocular disorders which could have influenced the 
vision 
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SAMPLE SIZE: 40 patients 
SCREENING PROCEDURES / VISITS: 
40 patients were diagnosed as NA-AION in acute phase.  
At the first visit- 
 Detailed history of present and past illness,drug and treatment 
H/O-Diabetes, Hypertension, Hyperlipidemia, Migraine, long term 
drug intake like amiodarone/alpha interferon 
 V/A using Snellen’s acuity chart 
 Pupillary reaction 
 Colour vision 
 Dilatation and fundus examination 
 Visual fields using Automated perimetry or Bjerrum screen 
 Fundus photography, FFA 
 ESR 
 Random blood sugar, complete hemogram, fasting lipid profile, 
Complete systemic evaluation by cardiologist and physician to rule 
out systemic association 
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METHODS: 
20 patients among them were randomly selected for steroid therapy 
with 60mg oral prednisolone once daily for 2 weeks, thereafter tapered by 
5mg every 5 days to 40mg either till the disc shows no edema or upto a 
maximum of 2 months and then rapidly tapered off. 20 other patients 
were treated with placebo (oral vitamin C 200 mg once daily) 
Informed consent was obtained from all patients 
FOLLOW UP PROCEDURES / VISITS: 
 Assesment of visual acuity,pupillary reaction and fundus examination 
every week.  
 Assessment of visual acuity and visual fields after completion of 
therapy and at the end of 6 months from the onset of symptoms 
 Adverse effects of corticosteroids were looked for. 
ASSESSMENT OF PARAMETERS: 
 Visual acuity   
 Visual fields   
 Optic disc edema 
RESULTS AND ANALYSIS 
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RESULTS AND ANALYSIS 
The study included 40 patients of NA-AION within two weeks of 
onset of symptoms 
Table 1: Number of cases 
Group Number of cases 
Steroid treated group 20 
Control group 20 
Total 40 
 
DEMOGRAPHIC DETAILS 
1.AGE  
All patients included in the study belong to the age group of 50 years 
and above 
 Mean age in steroid treated group was 54.3 years 
Mean age in control group was 53.9 years 
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2. SEX 
Males were more commonly involved than females. 
Table 2: Sex distribution 
Sex Steroid treated group Control group 
Male 13 11 
Female 7 9 
Total 20 20 
 
3. LATERALITY 
Chart 1: Laterality in steroid group 
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Chart 2: Laterality in control group 
3. SYSTEMIC ASSOCIATIONS 
 
 
 
 
 
 
 
Chart 3: Systemic associations in steroid and control groups 
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CLINICAL DETAILS 
1. OPTIC DISC EDEMA 
 
 
 
 
 
 
 
 
 
Chart 5: Hyperaemic and Pallid forms of disc edema 
 
 
 
 
 
 
Chart 6: Segmental and diffuse forms of disc edema 
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Table 3: Fundus in NA-AION 
Feature 
Steroid treated  
group 
Control 
group 
Splinter hemorrhages 9 7 
Small/ absent cup either eyes 14 12 
 
2. VISUAL FIELD DEFECT 
Table 4: Type of visual field defect 
Type of defect Steroid treated group Control group 
Altitudinal 8 15 
Sectoral 2 0 
Arcuate 0 0 
 
35 
 
VISUAL ACUITY 
Improvement / worsening- change in minimum two snellen lines 
Visual acuity change from initial visit to completion of therapy 
V/A at 
initial 
visit 
Steroid treated group Control group 
number 
of eyes 
improved worsened 
number 
of eyes 
improved worsened 
6/18-6/60 5 4 0 3 1 2 
6/60-3/60 3 2 0 5 2 2 
3/60-CF 6 3 0 7 1 3 
CF or 
worse 
6 3 0 5 0 0 
Total 20 12 0 20 4 7 
 
Visual acuity change from initial visit to 6 months from onset of disease 
V/A at 
initial 
visit 
Steroid treated group Control group 
number 
of eyes 
improved worsened 
number 
of eyes 
improved worsened 
6/18-6/60 5 5 0 3 1 2 
6/60-3/60 3 3 0 5 2 3 
3/60-CF 6 5 0 7 2 3 
CF or 
worse 
6 3 0 5 1 1 
Total 20 16 0 20 6 9 
 
There was significant improvement in V/A in steroid treated group 
than in control group- p value 0.001 
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VISUAL FIELDS 
Improvement in MS & retinal threshold sensitivity in Automated 
perimetry or reduction in the size of scotoma in manual fields- 
improvement 
Reduction in MS in Automated perimetry or expanding scotoma in 
manual fields- worsening 
Visual field defect change from initial visit to completion of therapy 
Steroid treated group Control group 
number 
of eyes 
improved worsened 
number 
of eyes 
improved worsened 
20 7 1 20 3 8 
 
Visual field defect change from initial visit to 6 months from onset of disease 
Steroid treated group Control group 
number of 
eyes 
improved worsened 
number of 
eyes 
improved worsened 
20 8 1 20 6 9 
 
There was significant improvement in visual field in steroid treated 
group than in control group- p value 0.01 
37 
 
OPTIC DISC EDEMA 
Early optic disc edema resolution - resolution in <6 weeks 
Optic disc edema resolution 
Parameter 
Steroid treated 
group 
Control group 
Mean duration (weeks) 4.6 7.5 
Early ODE resolution- 
number of eyes (%) 
14 (70%) 4 (20%) 
 
STATISTICAL ANALYSIS  
The data collected from all cases were recorded in a Master Chart. 
Data analysis was done with “Microsoft excel”. The results were 
analysed with Chi-square tests and p values were calculated. A p value of 
less than 0.05 is significant.  
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CLINICAL PHOTOGRAPHS 
    OD- normal                  OS- diffuse pallid disc edema                           
 
 
 
 
  
     FFA- OD- normal                 FFA-OS- disc leak 
 
 
 
 
OS- after 6 months- disc pallor 
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AP OS- BEFORE TREATMENT- INFERIOR ALTITUDINAL FIELD 
DEFECT 
MS-15.8 
LV-143 
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AP- OS – AFTER TREATMENT- INFERIOR ALTITUDINAL FIELD 
DEFECT – improvement in retinal threshold sensitivity is noted. 
MS- 17.5 
LV- 133 
DISCUSSION 
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DISCUSSION 
Though there are studies which conclude that there is no effective 
treatment for NA-AION, the role of corticosteroids in it has been studied 
since 1960s. This study was done to determine whether this therapy is 
beneficial in NA-AION patients in the early stage of presentation. By 
analysing our results we find the following: 
1.  Males are more commonly affected than females. 
2.  Diabetes mellitus, hypertension and hyperlipidemia were the 
common systemic associations observed. Smoking as an association 
was also observed in both the groups. But none of these associations 
were statistically significant. 
3.  Relative afferent pupillary defect was observed in 75% of the cases in 
both the groups. 
4.  Colour vision defect was observed in 90% of the cases in both the 
groups 
5.  The most common type of optic disc edema noted was hyperaemic 
and segmental type. Small or absent cup in the contralateral eye was 
seen in more than 50% of cases in both the groups 
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6.  FFA showed disc delay in 50% cases in both the groups and disc 
leakage was observed in 30% cases 
7.  The most common type of visual field defect observed was altitudinal 
especially inferior altitudinal.  
8.  A change in minimum of two Snellen lines was taken as improvement 
or worsening. There was 80% improvement in the steroid treated 
group and 30% in the control group. Irrespesctive of the visual acuity 
at onset, the improvement in steroid treated group was significant. 
None of the cases in the steroid treated group showed any worsening 
in visual acuity. The improvement in visual acuity was noted not only 
until completion of therapy, but even upto 6 months from the onset of 
NA-AION. 
9.  Similarly, the visual fields improved beyond completion of therapy 
upto 6 months. The retinal threshold sensitivity and mean sensitivity 
improved after treatment in the steroid group. It improved in 40% in 
the steroid treated group and 30% in the control group. 
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10. Early disc edema resolution was noted in 70% cases in the steroid 
treated group and 20% in the control group.  The average time taken 
for resolution of disc edema was 4.6 weeks in steroid treated group 
and 7.5 weeks in control group. 
11. Corticosteroid therapy did not have any deleterious effects on the 
visual acuity or visual fields. No serious systemic side effects were 
observed in any of the cases. 
 
   
CONCLUSION 
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CONCLUSION 
Oral corticosteroids if started within two weeks of onset of NA-AION 
is beneficial as it improves the visual acuity and visual fields and hastens 
the resolution of optic disc edema.  
LIMITATION 
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LIMITATION 
The strengths of this study are that it has a control group for 
comparison and randomization was followed during selection of groups. 
Though the effectiveness of corticosteroids has been proved in this study, 
it needs to be extended to a larger cohort. 
PART III 
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ABBREVIATION 
 AION- Anterior Ischaemic Optic Neuropathy 
 PION- Posterior Ischaemic Optic Neuropathy 
 NA-AION- Non-Arteritic Anterior Ischaemic Optic Neuropathy 
 PCA- Posterior Ciliary Arteries 
 SPCA- Short Posterior Ciliary Arteries 
 ONH- Optic Nerve Head 
 BP- Blood Pressure 
 IOP- Intra Ocular Pressure 
 ACL- Anti Cardio Lipin 
 A-AION- Arteritic Anterior Ischaemic Optic Neuropathy 
 AP- Automated Perimetry 
 FFA- Fundus Fluorescein Angiography 
 ESR- Erythrocyte Sedimentation Rate 
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 EOM- Extra Ocular Muscle 
 DM- Diabetes Mellitus 
 HTN- Hypertension 
 GCA- Giant Cell Arteritis 
 CRP- C Reactive Protein 
 RBS- Random Blood Sugar 
 CF- Counting Fingers 
 V/A- Visual acuity 
 MS- Mean Sensitivity 
 LV- Loss Variance 
 ODE- Optic Disc Edema 
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PROFORMA 
Name:                Age:              Sex: 
Occupation:            Address: 
Registration Number:                      Contact number: 
Presenting complaints: 
History of present illness: 
H/O defective vision: onset, progression, painful/painless,  
H/O defective field of vision 
H/O transient obscuration of vision & duration 
H/O headache- onset, progression, location, severity, diurnal variation, 
associated aura/blurring of vision/nausea/vomitting 
H/O claudication- jaw,neck or tongue 
Past history: 
H/O similar episodes in the past 
H/O Glaucoma 
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H/O Diabetes, Hypertension, Hyperlipidemia, Cerebrovascular accident, 
Myocardial infarction, Migraine 
H/O long term drug intake like amiodarone/ interferon alpha 
Personal history: 
H/O Smoking, H/O alcoholism 
GENERAL EXAMINATION 
Vital data - pulse rate,  blood pressure , peripheral pulses 
OCULAR EXAMINATION 
Induration of temporal artery region, decreased or absent temporal artery 
pulse, any cordlike firmness/nodularity of temporal artery, scalp 
tenderness     -Yes/No 
Parameters Right eye Left eye 
Best corrected Visual acuity using 
Snellen’s chart 
  
Extra ocular movements- ductions 
and versions 
  
Anterior segment examination with 
slit lamp 
 
  
52 
 
Pupil size, shape and reaction    
A dilated fundus examination with 
slit lamp biomicroscopy using 90D 
lens and Indirect Ophthalmoscopy 
using 20D lens-  
1.optic disc edema  hyperaemic/ 
pallid , diffuse/segmental  
2.Splinter haemorrhages  
3.Small or absent cup in either eyes 
  
Intra ocular pressure measurement by 
Applanation tonometry 
  
Colour vision   
Visual fields using automated 
perimetry by Octopus or Bjerrum 
screen (if visual acuity is poor)- 
1.Altitudinal defect/ Sectoral defect/ 
Arcuate defect 
2. Mean sensitivity 
  
Fundus flourescein angiography-  
1.Disc delay 
2.Choroidal delay 
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INVESTIGATIONS: 
Blood sugar 
Complete haemogram with ESR / C- reactive protein 
Fasting Lipid profile  
Complete systemic evaluation by General physician, Cardiologist to rule 
out systemic association 
DIAGNOSIS-Non Arteritic Anterior Ischaemic Optic Neuropathy  
TREATMENT- Oral Prednisolone 1mg/kg body weight once daily 
tapered by 5mg every week either till the disc shows no edema or upto a 
maximum period of 2 months 
FOLLOW-UP: Every week until completion of therapy & at 6 months 
fromthe onset of disease. Assessment of  
 Visual acuity 
 Visual fields 
 Rate of resolution of optic disc edema 
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MASTER CHART 
Sr. 
No 
Name Age sex eye V/A 
Systemic 
conditions 
pupil 
Colour 
vision 
FUNDUS AP FFA V/A Field 
ODE 
resolution 
V/A field 
1 Samraj 51 M L 6/36 - RAPD Def P,S,sh IA DD 6/18 IA 3 6/18 IA 
2 Loganathan 59 M R 6/36 HTN,HL RAPD Def P,S,sc IA DD 6/18 IA 3 6/18 IA 
3 Varadaraj 55 F R 6/36 HTN,HL RAPD Def H,S,sh,sc IA DL 6/18 IA 4 6/18 IA 
4 Karunakaran 59 M L 6/60 DM,HTN,HL,smk RAPD Def P,S,sc IA DD 6/36 IA 7 6/24 IA 
5 Shanthamma 50 M R 1/60 DM,HTN,HL RAPD Def H,D,sc IA DD 2/60 IA 5 3/60 IA 
6 Rani 58 F L 2/60 DM,HTN,HL RAPD Def H,S,sh IA DD 2/60 IA 4 3/60 IA 
7 Sulochana 51 F R 6/60 DM,HTN,HL RTL N P,S,sh IA DD 5/60 IA 6 2/60 IA 
8 Ravi 54 M R 3/60 HTN,smk RAPD Def P,S,sh,sc IA DD 5/60 IA 4 5/60 IA 
9 Mohammed ali 55 M L CF DM,HL,smk RAPD Def H,S,sh NP DD CF NP 8 CF NP 
10 Daniel 53 M L CF DM,HTN,smk RAPD Def H,S NP NP CF NP 9 CF NP 
11 Krishnan 50 M R HM HTN RAPD Def P,S,sh NP DD HM NP 9 HM NP 
12 Maniraj 51 M L 1/60 HL,smk RTL N P,S,sh IA DD 3/60 IA 4 4/60 IA 
13 Revathi 57 F R 6/36 DM,HL RTL N H,D,sc SA DD 6/36 SA 6 6/18 SA 
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Sr. 
No 
Name Age sex eye V/A 
Systemic 
conditions 
pupil 
Colour 
vision 
FUNDUS AP FFA V/A Field 
ODE 
resolution 
V/A field 
14 Kumar 52 M L 2/60 DM,HTN,HL,smk RAPD Def P,S,sc IA NP 4/60 IA 4 5/60 IA 
15 Gomathi 54 F L 6/36 DM,HTN,HL RAPD Def H,D,sc IA DD 6/24 IA 5 6/18 IA 
16 Premkumar 53 M L CF HTN,smk RAPD Def H,S,sc NP DD CF NP 9 CF NP 
17 Kumari 50 F L HM DM,HTN,HL RTL N H,S,sc IA DL HM IA 5 HM IA 
18 Lakshmi 60 F L 6/60 HTN,HL RAPD Def P,S,sh,sc IA DD 5/60 IA 4 3/60 IA 
19 Velmurugan 55 M L 4/60 DM,smk RAPD Def H,D NP DL 4/60 NP 8 4/60 NP 
20 Haridoss 52 M R HM DM,HTN RAPD Def H,D NP DD HM NP 9 2/60 NP 
21 Balan 57 M R 5/60 DM,HTN,HL,smk RAPD Def P,S,sc NP DD 5/60 NP 9 5/60 NP 
22 Justin 54 M L 4/60 - RTL Def H,D IA DD 4/60 IA 4 4/60 IA 
23 Prabakaran 55 M L CF HTN,smk RTL Def H,D,sh,sc IA DL CF IA 6 HM IA 
24 Muthulakshmi 53 F L HM DM,HTN,HL RAPD Def P,S,sh IA NP HM IA 5 HM IA 
25 Visalaakshi 56 F L CF DM,HTN.HL RTL Def H,D,sc IA NP 3/60 IA 7 3/60 IA 
26 Sundar 52 M L 4/60 DM,HTN,HL,smk RAPD Def H,D NP DD 4/60 NP 8 5/60 NP 
27 Ananthi 58 F R 3/60 - RAPD Def P,S,sh NP DD 5/60 NP 8 6/60 NP 
28 Gopal 55 M R CF DM,HTN,HL,smk RAPD Def H,D,sc IA DL 2/60 IA 4 2/60 IA 
56 
 
Sr. 
No 
Name Age sex eye V/A 
Systemic 
conditions 
pupil 
Colour 
vision 
FUNDUS AP FFA V/A Field 
ODE 
resolution 
V/A field 
29 Kumaran 50 M R 4/60 DM,HTN,smk RTL Def H,D,sh,sc IA NP 4/60 IA 6 6/60 IA 
30 Rosy 54 F R 1/60 - RAPD Def H,D,sh,sc Sec DD 3/60 Sec 5 4/60 Sec 
31 Subbamma 56 F L 4/60 DM,HTN,HL RAPD Def H,S,sc NP DL 4/60 NP 8 6/60 NP 
32 Palanimuthu 60 M R 5/60 DM,HTN,HL RAPD Def H,D,sc NP NP 3/60 NP 7 2/60 NP 
33 Kuppan 52 M L 5/60 - RAPD Def H,D,sc Sec DL 4/60 Sec 5 1/60 Sec 
34 Kamatchi 58 F R 2/60 DM,HTN,HL RAPD Def H,S,sc NP DD 1/60 NP 9 1/60 NP 
35 Seethamma 51 F L 4/60/ Mig RAPD Def P,S,sh NP DL 3/60 NP 7 2/60 NP 
36 Jeevan 54 M R HM DM,HTN,smk RAPD Def H,D,sc NP NP 1/60 NP 7 3/60 NP 
37 Kamali 53 F R 5/60 HL RTL Def H,D,sc IA DD 6/60 IA 6 6/36 IA 
38 Rajan 55 M R 4/60 DM,HTN,HL,smk RTL Def H,S,sc IA NP 5/60 IA 4 6/60 IA 
39 Rukku 52 F L 5/60 - RAPD Def H,D,sh,sc IA DL 6/60 IA 6 6/36 IA 
40 Murugan 50 M R 4/60 DM,HTN,HL,smk RAPD Def H,S,sc NP DL 5/60 NP 9 6/36 NP 
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KEY TO MASTER CHART 
 M-male 
 F-female 
 L-left eye 
 R-right eye 
 CF-counting fingers 
 HM-hand movements 
 DM-diabetes mellitus 
 HTN-hypertension 
 HL-hyperlipidemia 
 Smk-smoking 
 Mig-migraine 
 RTL-reacting to light 
 RAPD-relative afferent pupillary defect 
 Def-defective 
 N-normal 
 P-pallid 
 H-hyperaemic 
 S-segmental 
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 D-diffuse 
 Sc-small cup 
 Sh-splinter hemorrhage 
 IA-inferior altitudinal 
 SA-superior altitudinal 
 Sec-sectoral 
 NP-not possible 
 DL-disc leak 
 DD-disc delay 
